Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
People with HIV (PWH) are facing multiple challenges in the battle against weight gain, including the growing, worldwide obesity epidemic and its drivers, normal aging and HIV- and antiretroviral therapy (ART)-associated contributors. The worldwide obesity epidemic is beyond the scope of this talk but must be considered when assessing individual patient risk and treatment options.…
This presentation will explore the lived experience of women living with HIV (WLWH) as they navigate menopause and the intersections with HIV and aging stigma. As a woman living with HIV, I also intend to briefly touch on the clinical care experience from the patient perspective and its impact on engagement in care. WLWH have…
This presentation will discuss HIV incidence during pregnancy and breastfeeding as well as factors (hormonal, immunological, behavioural, sexual and genital infections, and low male participation in antenatal care and HIV testing) that increase risk of HIV acquisition this period. In addition, we will look at the contribution of acute HIV infection to vertical HIV infection…
Antiretroviral therapy (ART) has transformed HIV-1 infection from a fatal disease into a manageable chronic condition. However, longitudinal studies reveal that the decay rate of the HIV-1 reservoir is so slow that ART alone cannot eliminate the reservoir within the lifetime of people living with HIV-1 (PLWH). This underscores the urgent need for safe and…
Long Covid is a disabling post-viral disease state that impacts over 400 million people worldwide, with no effective treatment currently available. Despite incomplete mechanistic understanding, lack of clinically actionable biomarkers, and insufficient policymaker recognition, significant progress has been made in recent years, revealing a clear histological and pathophysiological basis for the condition. SARS-CoV-2 infection prompts…
Is testing the key to unlocking PrEP scale-up? The use of antiretroviral drugs (ARVs) to prevent new HIV infections has been well-established for decades, particularly in the context of pre-exposure prophylaxis (PrEP). Yet, only an estimated 2.5 million people are currently using PrEP—far fewer than the 10 million needed to meet global HIV prevention goals…
As a lentivirus, HIV is capable of infecting non-dividing cells. For decades it has been understood that HIV must be able to deliver its genetic material across the nuclear envelope in order to establish infection. As the gatekeeper between the cytoplasm and the nucleus, the nuclear pore complex (NPC) represents an obvious entry point. During…
HIV-1 persists in a mostly latent state within blood and tissues during suppressive ART. Proviral integration sites may play a critical role in the establishment and maintenance of this latent reservoir. Understanding the landscape of proviral integration is essential for deciphering the mechanisms behind HIV-1 latency and reactivation. Recent studies have shed light on the…
Long-acting injectable formulations are revolutionizing HIV treatment and prevention and have similar potential to improve the treatment and prevention of tuberculosis, including simpler, shorter regimens and expanded treatment options. This presentation will describe how long-acting injectable formulations could address important obstacles to ending the world’s oldest pandemic, review recent progress in the development of long-acting…
Today’s ART paradigm is characterized by the availability of potent drugs for HIV prevention and treatment, including second-generation integrase strand transfer inhibitors (INSTIs) like dolutegravir (DTG). INSTIs block the integration of viral DNA into the host genome, a critical step in HIV’s life cycle. The integrase (IN) gene, a highly conserved region of the HIV…